Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
11 02 2020
Historique:
received: 04 12 2018
accepted: 07 01 2020
entrez: 13 2 2020
pubmed: 13 2 2020
medline: 24 4 2020
Statut: epublish

Résumé

The protein inhibitor of activated STAT1 (PIAS1) is an E3 SUMO ligase that plays important roles in various cellular pathways. Increasing evidence shows that PIAS1 is overexpressed in various human malignancies, including prostate and lung cancers. Here we used quantitative SUMO proteomics to identify potential substrates of PIAS1 in a system-wide manner. We identified 983 SUMO sites on 544 proteins, of which 62 proteins were assigned as putative PIAS1 substrates. In particular, vimentin (VIM), a type III intermediate filament protein involved in cytoskeleton organization and cell motility, was SUMOylated by PIAS1 at Lys-439 and Lys-445 residues. VIM SUMOylation was necessary for its dynamic disassembly and cells expressing a non-SUMOylatable VIM mutant showed a reduced level of migration. Our approach not only enables the identification of E3 SUMO ligase substrates but also yields valuable biological insights into the unsuspected role of PIAS1 and VIM SUMOylation on cell motility.

Identifiants

pubmed: 32047143
doi: 10.1038/s41467-020-14581-w
pii: 10.1038/s41467-020-14581-w
pmc: PMC7012886
doi:

Substances chimiques

Cytoskeletal Proteins 0
PIAS1 protein, human 0
Protein Inhibitors of Activated STAT 0
SUMO-1 Protein 0
Small Ubiquitin-Related Modifier Proteins 0
Vimentin 0
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

834

Références

Flotho, A. & Melchior, F. in Annual Review of Biochemistry. Vol. 82, 357–385 (Annual Reviews, 2013).
Liang, Y. C. et al. SUMO5, a novel poly-SUMO isoform, regulates PML nuclear bodies. Sci. Rep. 6, 15 (2016).
doi: 10.1038/s41598-016-0008-1
Kunz, K., Piller, T. & Muller, S. SUMO-specific proteases and isopeptidases of the SENP family at a glance. J. Cell Sci. 131, pii: jcs211904 (2018).
Mukhopadhyay, D. & Dasso, M. Modification in reverse: the SUMO proteases. Trends Biochem. Sci. 32, 286–295 (2007).
doi: 10.1016/j.tibs.2007.05.002 pubmed: 17499995 pmcid: 17499995
Liu, B. & Shuai, K. Regulation of the sumoylation system in gene expression. Curr. Opin. Cell Biol. 20, 288–293 (2008).
doi: 10.1016/j.ceb.2008.03.014 pubmed: 18468876 pmcid: 18468876
Sampson, D. A., Wang, M. & Matunis, M. J. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SURIO-1 modification. J. Biol. Chem. 276, 21664–21669 (2001).
doi: 10.1074/jbc.M100006200 pubmed: 11259410 pmcid: 11259410
Johnson, E. S. Protein modification by SUMO. Annu. Rev. Biochem. 73, 355–382 (2004).
doi: 10.1146/annurev.biochem.73.011303.074118 pubmed: 15189146 pmcid: 15189146
Shuai, K. & Liu, B. Regulation of gene-activation pathways by pias proteins in the immune system. Nat. Rev. Immunol. 5, 593–605 (2005).
doi: 10.1038/nri1667 pubmed: 16056253 pmcid: 16056253
Rytinki, M. M., Kaikkonen, S., Pehkonen, P., Jaaskelainen, T. & Palvimo, J. J. PIAS proteins: pleiotropic interactors associated with SUMO. Cell. Mol. Life Sci. 66, 3029–3041 (2009).
doi: 10.1007/s00018-009-0061-z pubmed: 19526197 pmcid: 19526197
Tan, J. A. T., Song, J., Chen, Y. & Durrin, L. K. Phosphorylation-dependent interaction of SATB1 and PIAS1 directs SUMO-regulated caspase cleavage of SATB1. Mol. Cell. Biol. 30, 2823–2836 (2010).
doi: 10.1128/MCB.01603-09 pubmed: 20351170 pmcid: 20351170
Okubo, S. et al. NMR structure of the N-terminal domain of SUMO ligase PIAS1 and its interaction with tumor suppressor p53 and A/T-rich DNA oligomers. J. Biol. Chem. 279, 31455–31461 (2004).
doi: 10.1074/jbc.M403561200 pubmed: 15133049 pmcid: 15133049
Kipp, M. et al. SAF-Box, a conserved protein domain that specifically recognizes scaffold attachment region DNA. Mol. Cell. Biol. 20, 7480–7489 (2000).
doi: 10.1128/MCB.20.20.7480-7489.2000 pubmed: 11003645 pmcid: 11003645
van den Akker, E. et al. FLI-1 functionally interacts with PIASx alpha, a member of the PIAS E3 SUMO ligase family. J. Biol. Chem. 280, 38035–38046 (2005).
doi: 10.1074/jbc.M502938200 pubmed: 16148010 pmcid: 16148010
Duval, D., Duval, G., Kedinger, C., Poch, O. & Boeuf, H. The ‘PINIT’ motif, of a newly identified conserved domain of the PIAS protein family, is essential for nuclear retention of PIAS3L. FEBS Lett. 554, 111–118 (2003).
doi: 10.1016/S0014-5793(03)01116-5 pubmed: 14596924 pmcid: 14596924
Palvimo, J. J. PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription. Biochem. Soc. Trans. 35, 1405–1408 (2007).
doi: 10.1042/BST0351405 pubmed: 18031232 pmcid: 18031232
Kahyo, T., Nishida, T. & Yasuda, H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell 8, 713–718 (2001).
doi: 10.1016/S1097-2765(01)00349-5 pubmed: 11583632 pmcid: 11583632
Gross, M. et al. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 20, 3880–3887 (2001).
doi: 10.1038/sj.onc.1204489 pubmed: 11439351 pmcid: 11439351
Megidish, T., Xu, J. H. & Xu, C. W. Activation of p53 by protein inhibitor of activated Stat1 (PIAS1). J. Biol. Chem. 277, 8255–8259 (2002).
doi: 10.1074/jbc.C200001200 pubmed: 11788578 pmcid: 11788578
Liu, B. et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc. Natl Acad. Sci. USA 95, 10626–10631 (1998).
doi: 10.1073/pnas.95.18.10626 pubmed: 9724754 pmcid: 9724754
Driscoll, J. J. et al. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood 115, 2827–2834 (2010).
doi: 10.1182/blood-2009-03-211045 pubmed: 19965618 pmcid: 19965618
Hoefer, J. et al. PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am. J. Pathol. 180, 2097–2107 (2012).
doi: 10.1016/j.ajpath.2012.01.026 pubmed: 22449952 pmcid: 22449952
Puhr, M. et al. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. Oncogene 35, 2322–2332 (2016).
doi: 10.1038/onc.2015.292 pubmed: 26257066 pmcid: 26257066
Rabellino, A. et al. PIAS1 promotes lymphomagenesis through MYC upregulation. Cell Rep. 15, 2266–2278 (2016).
doi: 10.1016/j.celrep.2016.05.015 pubmed: 27239040 pmcid: 27239040
Kadare, G. et al. PIAS1-mediated sumoylation of focal adhesion kinase activates its autophosphorylation. J. Biol. Chem. 278, 47434–47440 (2003).
doi: 10.1074/jbc.M308562200 pubmed: 14500712 pmcid: 14500712
Streich, F. C. & Lima, C. D. Capturing a substrate in an activated RING E3/E2-SUMO complex. Nature 536, 304 (2016).
doi: 10.1038/nature19071 pubmed: 27509863 pmcid: 27509863
Rabellino, A. et al. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res. 72, 2275–2284 (2012).
doi: 10.1158/0008-5472.CAN-11-3159 pubmed: 22406621 pmcid: 22406621
Lamoliatte, F., McManus, F. P., Maarifi, G., Chelbi-Alix, M. K. & Thibault, P. Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification. Nat. Commun. 8, 11 (2017).
doi: 10.1038/ncomms14109
McManus, F. P., Lamoliatte, F. & Thibault, P. Identification of cross talk between SUMOylation and ubiquitylation using a sequential peptide immunopurification approach. Nat. Protoc. 12, 2342–2358 (2017).
doi: 10.1038/nprot.2017.105 pubmed: 29048423 pmcid: 29048423
Hendriks, I. A. et al. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat. Struct. Mol. Biol. 21, 927–936 (2014).
doi: 10.1038/nsmb.2890 pubmed: 25218447 pmcid: 25218447
Goodman, S. R. Medical Cell Biology (Academic Press, 2007).
Hochstrasser, M. SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 107, 5–8 (2001).
doi: 10.1016/S0092-8674(01)00519-0 pubmed: 11595179 pmcid: 11595179
Brown, J. R. et al. SUMO ligase protein inhibitor of activated STAT1 (PIAS1) is a constituent promyelocytic leukemia nuclear body protein that contributes to the intrinsic antiviral immune response to herpes simplex virus 1. J. Virol. 90, 5939–5952 (2016).
doi: 10.1128/JVI.00426-16 pubmed: 27099310 pmcid: 27099310
Keusekotten, K. et al. Multivalent interactions of the SUMO-interaction motifs in RING finger protein 4 determine the specificity for chains of the SUMO. Biochem. J. 457, 207–214 (2014).
doi: 10.1042/BJ20130753 pubmed: 24151981 pmcid: 24151981
McManus, F. P. et al. Quantitative SUMO proteomics reveals the modulation of several PML nuclear body associated proteins and an anti-senescence function of UBC9. Sci. Rep. 8, 7754 (2018).
doi: 10.1038/s41598-018-25150-z pubmed: 29773808 pmcid: 29773808
Lane, E. B., Hogan, B. L. M., Kurkinen, M. & Garrels, J. I. Co-expression of vimentin and cytokeratins in parietal endoderm cells of early mouse embryo. Nature 303, 701–704 (1983).
doi: 10.1038/303701a0 pubmed: 6190091 pmcid: 6190091
Ramaekers, F. C. S. et al. Coexpression of keratin-type and vimentin-type intermediate filaments in human metastatic carcinoma-cells. Proc. Natl Acad. Sci. USA Biol. Sci. 80, 2618–2622 (1983).
doi: 10.1073/pnas.80.9.2618
Thomas, J. T., Hubert, W. G., Ruesch, M. N. & Laimins, L. A. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc. Natl Acad. Sci. USA 96, 8449–8454 (1999).
doi: 10.1073/pnas.96.15.8449 pubmed: 10411895 pmcid: 10411895
Anastasi, E. et al. Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes. Eur. J. Endocrinol. 141, 644–652 (1999).
doi: 10.1530/eje.0.1410644 pubmed: 10601969 pmcid: 10601969
Chu, Y. W., Runyan, R. B., Oshima, R. G. & Hendrix, M. J. C. Expression of complete keratin filaments in mouse l-cells augments cell-migration and invasion. Proc. Natl Acad. Sci. USA 90, 4261–4265 (1993).
doi: 10.1073/pnas.90.9.4261 pubmed: 7683431 pmcid: 7683431
Bordeleau, F., Bessard, J., Sheng, Y. & Marceau, N. Keratin contribution to cellular mechanical stress response at focal adhesions as assayed by laser tweezers. Biochem. Cell Biol. 86, 352–359 (2008).
doi: 10.1139/O08-076 pubmed: 18756330 pmcid: 18756330
Hu, G., Jia, F., Gao, N. & Han, Y. Impacts of cyhospitalclinE downstream vimentin on proliferation, invasion and apoptosis of hepatoma HepG2 cell. Int. J. Clin. Exp. Med. 11, 5564–5571 (2018).
Snider, N. T. & Omary, M. B. Post-translational modifications of intermediate filament proteins: mechanisms and functions. Nat. Rev. Mol. Cell Biol. 15, 163–177 (2014).
doi: 10.1038/nrm3753 pubmed: 24556839 pmcid: 24556839
Zhu, Q. S. et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 30, 457–470 (2011).
doi: 10.1038/onc.2010.421 pubmed: 20856200 pmcid: 20856200
Snider, N. T., Weerasinghe, S. V. W., Iniguez-Lluhi, J. A., Herrmann, H. & Omary, M. B. Keratin hypersumoylation alters filament dynamics and is a marker for human liver disease and keratin mutation. J. Biol. Chem. 286, 2273–2284 (2011).
doi: 10.1074/jbc.M110.171314 pubmed: 21062750 pmcid: 21062750
Eriksson, J. E. et al. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J. Cell Sci. 117, 919–932 (2004).
doi: 10.1242/jcs.00906 pubmed: 14762106 pmcid: 14762106
Helfand, B. T. et al. Vimentin organization modulates the formation of lamellipodia. Mol. Biol. Cell 22, 1274–1289 (2011).
doi: 10.1091/mbc.e10-08-0699 pubmed: 21346197 pmcid: 21346197
Perez-Sala, D. et al. Vimentin filament organization and stress sensing depend on its single cysteine residue and zinc binding. Nat. Commun. 6, 7287 (2015).
Satelli, A. & Li, S. L. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 68, 3033–3046 (2011).
doi: 10.1007/s00018-011-0735-1 pubmed: 21637948 pmcid: 21637948
Robert, A., Rossow, M. J., Hookway, C., Adam, S. A. & Gelfand, V. I. Vimentin filament precursors exchange subunits in an ATP-dependent manner. Proc. Natl Acad. Sci. USA 112, E3505–E3514 (2015).
doi: 10.1073/pnas.1505303112 pubmed: 26109569 pmcid: 26109569
Premchandar, A. et al. Structural dynamics of the vimentin coiled-coil contact regions involved in filament assembly as revealed by hydrogen-deuterium exchange. J. Biol. Chem. 291, 24931–24950 (2016).
doi: 10.1074/jbc.M116.748145 pubmed: 27694444 pmcid: 27694444
Chou, Y. H., Khuon, S., Herrmann, H. & Goldman, R. D. Nestin promotes the phosphorylation-dependent disassembly of vimentin intermediate filaments during mitosis. Mol. Biol. Cell 14, 1468–1478 (2003).
doi: 10.1091/mbc.e02-08-0545 pubmed: 12686602 pmcid: 12686602
Chen, P. et al. Protein inhibitor of activated STAT-1 is downregulated in gastric cancer tissue and involved in cell metastasis. Oncol. Rep. 28, 2149–2155 (2012).
doi: 10.3892/or.2012.2030 pubmed: 22972521 pmcid: 22972521
Suman, P. et al. AP-1 transcription factors, mucin-type molecules and MMPs regulate the IL-11 mediated invasiveness of JEG-3 and HTR-8/SVneo trophoblastic cells. PLoS ONE 7, 12 (2012).
doi: 10.1371/journal.pone.0029745
Cuijpers, S. A. G., Willemstein, E. & Vertegaal, A. C. O. Converging small ubiquitin-like modifier (SUMO) and ubiquitin signaling: improved methodology identifies co-modified target proteins. Mol. Cell. Proteom. 16, 2281–2295 (2017).
doi: 10.1074/mcp.TIR117.000152
Kumar, R., Gonzalez-Prieto, R., Xiao, Z. Y., Verlaan-de Vries, M. & Vertegaal, A. C. O. The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery. Nat. Commun. 8, 1809 (2017).
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
doi: 10.1038/nbt.1511 pubmed: 19029910 pmcid: 19029910
Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805 (2011).
doi: 10.1021/pr101065j pubmed: 21254760 pmcid: 21254760
Feuermann, M., Gaudet, P., Mi, H. Y., Lewis, S. E. & Thomas, P. D. Large-scale inference of gene function through phylogenetic annotation of Gene Ontology terms: case study of the apoptosis and autophagy cellular processes. Database 2016, baw155 (2016).
Mi, H. Y. et al. PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. 45, D183–D189 (2017).
doi: 10.1093/nar/gkw1138 pubmed: 27899595 pmcid: 27899595
Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).
doi: 10.1093/nar/gkn923
Colaert, N., Helsens, K., Martens, L., Vandekerckhove, J. & Gevaert, K. Improved visualization of protein consensus sequences by iceLogo. Nat. Methods 6, 786–787 (2009).
doi: 10.1038/nmeth1109-786 pubmed: 19876014 pmcid: 19876014
Petersen, B., Petersen, T. N., Andersen, P., Nielsen, M. & Lundegaard, C. A generic method for assignment of reliability scores applied to solvent accessibility predictions. BMC Struct. Biol. 9, 10 (2009).
doi: 10.1186/1472-6807-9-51
von Mering, C. et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 31, 258–261 (2003).
doi: 10.1093/nar/gkg034
Szklarczyk, D. et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561–D568 (2011).
doi: 10.1093/nar/gkq973 pubmed: 21045058 pmcid: 21045058
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
doi: 10.1101/gr.1239303 pubmed: 14597658 pmcid: 14597658
Cline, M. S. et al. Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2, 2366–2382 (2007).
doi: 10.1038/nprot.2007.324 pubmed: 17947979 pmcid: 17947979

Auteurs

Chongyang Li (C)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada.
Molecular Biology Program, Université de Montréal, Montréal, Canada.

Francis P McManus (FP)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada.

Cédric Plutoni (C)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada.

Cristina Mirela Pascariu (CM)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada.

Trent Nelson (T)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada.
Molecular Biology Program, Université de Montréal, Montréal, Canada.

Lara Elis Alberici Delsin (LE)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada.
Molecular Biology Program, Université de Montréal, Montréal, Canada.

Gregory Emery (G)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada.
Department of Pathology and Cell Biology, Université de Montréal, Montréal, Québec, Canada.

Pierre Thibault (P)

Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada. pierre.thibault@umontreal.ca.
Department of Chemistry, Université de Montréal, Montréal, Québec, Canada. pierre.thibault@umontreal.ca.
Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada. pierre.thibault@umontreal.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH